Brief: Poxel Updates On PXL065 Phase 1A Single Ascending Dose Trial

Poxel SA

08/04/2019 17:15

April 8 (Reuters) - POXEL SA  POXEL.PA :
    * POXEL ANNOUNCES FAVORABLE RESULTS FOR PXL065 PHASE 1A SINGLE ASCENDING
DOSE
TRIAL
    * PXL065 OBSERVED TO HAVE A FAVORABLE SAFETY, TOLERABILITY AND
PHARMACOKINETIC
PROFILE IN PHASE 1A TRIAL
    * BASED ON FAVORABLE RESULTS IN PHASE 1A STUDY, COMPANY IS PREPARING TO
INITIATE A
PHASE 1B MAD TRIAL
    * DURING THE REMAINDER OF 2019, PREPARATION FOR THE PIVOTAL PHASE 2 
PROGRAM OF PXL065 IN BIOPSY-PROVEN NASH PATIENTS WILL ALSO INCLUDE A 
PRE-INVESTIGATIONAL NEW DRUG MEETING WITH THE U.S. FDA TO DISCUSS THE NASH
DEVELOPMENT STRATEGY

Source text for Eikon:  ID:nBw12r6Kwa 
Further company coverage:  POXEL.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))